MedTrace Logo

Clinical Study of CD19 CAR-T in the Treatment of Refractory Systemic Sclerosis

NCT06792344 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-12-22

No results posted yet for this study

Summary

This is an investigator-initiated trial aimed at assessing the safety and efficacy of anti-CD19 CAR-T cells in the treatment of childhood-onset systemic sclerosis

Conditions

  • Systemic Sclerosis (SSc)

Interventions

OTHER

anti-CD19 CAR-T cells

Intravenous injection the targeting CD19 CAR T cell

DRUG

anti-CD19 CAR-T cells

CD19-targeting CAR-T cells

Sponsors & Collaborators

  • Guangzhou Women and Children's Medical Center

    collaborator OTHER

  • The Children's Hospital of Zhejiang University School of Medicine

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
5 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-15
Primary Completion
2027-12-30
Completion
2027-12-30

Countries

  • China
  • Christmas Island

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06792344 on ClinicalTrials.gov